Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.47 |
| ▸ | FNTB | P49356 | 7/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21414462 | 0.86 | FNTA (0.47) | FNTAFNTBNPC1KMT2AMEN1 | |
| SCHEMBL20203639 | 0.85 | FNTA (0.45) | FNTAFNTBKDRNPC1RAB9A | |
| SCHEMBL18819899 | 0.82 | MEN1 (0.44) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL18819905 | 0.80 | CDK1 (0.43) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL21414492 | 0.79 | ALDH1A1 (0.42) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL7011414 | 0.77 | NOTUM (0.53) | KMT2AMEN1ALDH1A1GRM5 | |
| SCHEMBL18819901 | 0.76 | CDK4 (0.39) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL21414422 | 0.72 | KDR (0.40) | KDRKMT2AMEN1ALDH1A1 | |
| SCHEMBL23733466 | 0.72 | FNTA (0.44) | FNTAFNTBNPC1KMT2AMEN1 | |
| SCHEMBL21451835 | 0.72 | ACE (0.39) | NPC1RAB9AKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | FNTA 4431/4885FNTB 4849/4885KDR 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.